




IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

First Named Inventor:	Rajinder Singh	Examiner:	Unknown
Application No.:	10/631,029	Group Art Unit:	1632
Filing Date:	July 29, 2003		
Title:	Methods of Treating or Preventing Autoimmune Diseases with 2,4-Pyrimidinediamine Compounds		

**SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT
UNDER 37 CFR § 1.97(B) & 1.97(E)(1)**

Commissioner for Patents
P. O. Box 1450
Alexandria, VA 22313-1450

I hereby certify that this document is being sent via First Class U.S. mail addressed to Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on this 21 day of December, 2004.


Barbara A. Avery

Dear Sir:

Pursuant to 37 CFR § 1.97(b), the references listed on the attached Form PTO-1449 (2 sheets, submitted in duplicate) are brought to the attention of the Examiner for consideration in connection with the examination of the above-identified patent application. Copies of the identified references are enclosed as necessary. This Supplemental Information Disclosure Statement is being filed before the mailing of a first office action on the merits. In accordance with 37 CFR § 1.97(b), no statement or fee is required.

Pursuant to 37 CFR § 1.97(e)(1), the identified references (WO 03/018021, WO 03/063794, and WO 2004/014382) were cited by the International Searching Authority in the corresponding PCT Application. A copy of the PCT International Search Report is enclosed. The references WO 03/018021, WO 03/063794, and WO 2004/014382 contained in this IDS was first cited in a communication from a foreign patent office in a counterpart foreign application (PCT Application) not more than three months prior to the filing of this Supplemental Information Disclosure Statement.

Pursuant to the Manual of Patent Examining Procedure, Chapter 609, applicant requests that the Examiner consider each of the listed documents and initial and return to the undersigned a copy of the enclosed Form PTO/SB/08A (submitted in duplicate).

Date: December 21, 2004

Respectfully submitted,

DORSEY & WHITNEY LLP

Customer Number 25763

By: 

Scott D. Rothenberger, Reg. No. 41,277
Intellectual Property Department
Suite 1500
50 South Sixth Street
Minneapolis, MN 55402-1498
(612) 340-8819



Substitute for Form 1449A/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Application Number 10/631,029

Filing Date July 29, 2003

First Named Inventor Rajinder Singh

Art Unit 1632

Examiner Name Unknown

Sheet 1 of 2 Attorney Docket Number 28575/US/US

U.S. PUBLISHED DOCUMENTS

*Examiner Initials	Cite No.	DOCUMENT NUMBER Number - Kind Code (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		US- 2003/0165873	09-04-2003	Come et al.	
		US- 2004/0043388	03-04-2004	Come et al.	
		US- 2004/0122029	06-24-2004	Liu et al.	

FOREIGN PATENT DOCUMENTS

*Examiner Initial	Cite No.	FOREIGN PATENT DOCUMENT		Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	TRANSLATION	
		Country Code:	Number - Kind Code (if known)				YES	NO
		WO	2004/054617	07-01-2004	Kyowa Hakko Kogyo Co.		<input type="checkbox"/>	<input type="checkbox"/>
		WO	2004/080980	09-23-2004	Novartis A.G.		<input type="checkbox"/>	<input type="checkbox"/>
		WO	2004/074262	09-02-2004	Tibotec Pharmaceuticals, Inc.		<input type="checkbox"/>	<input type="checkbox"/>
		WO	2004/074244	09-02-2004	SmithKline Beecham Corporation		<input type="checkbox"/>	<input type="checkbox"/>
		WO	2004/069812	08-19-2004	Janssen Pharmaceutica N.V.		<input type="checkbox"/>	<input type="checkbox"/>
		WO	2004/056786	07-08-2004	Pfizer Products Inc., USA		<input type="checkbox"/>	<input type="checkbox"/>
		WO	2004/050068	06-17-2004	Janssen Pharmaceutica N.V., Belg.		<input type="checkbox"/>	<input type="checkbox"/>
		WO	2004/048343	06-10-2004	Schering AG		<input type="checkbox"/>	<input type="checkbox"/>
		WO	2004/046118	06-03-2004	Bayer Pharmaceuticals Corp.		<input type="checkbox"/>	<input type="checkbox"/>
		WO	2004/039359	05-13-2004	Bayer Pharmaceuticals Corp.		<input type="checkbox"/>	<input type="checkbox"/>
		WO	2004/002964	01-08-2004	Yamanouchi Pharmaceutical Co.		<input type="checkbox"/>	<input type="checkbox"/>

EXAMINER SIGNATURE

DATE CONSIDERED

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.



Substitute for form 1449A/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(use as many sheets as necessary)</i>				Application Number		10/631,029	
				Filing Date		July 29, 2003	
				First Named Inventor		Rajinder Singh	
				Art Unit		1632	
				Examiner Name		Unknown	
Sheet	2	of	2	Attorney Docket Number		28585/US/US	
FOREIGN PATENT DOCUMENTS							
*Examiner Initial	Cite No.	FOREIGN PATENT DOCUMENT		Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	TRANSLATION
		WO	03/094920	11-20-2003	Tibotec Pharmaceuticals		<input type="checkbox"/> <input type="checkbox"/>
		WO	03/045923	06-05-2003	Sankyo Company Limited		<input type="checkbox"/> <input type="checkbox"/>
		WO	2004/074261	09-02-2004	Tibotec Pharmaceuticals		<input type="checkbox"/> <input type="checkbox"/>
		WO	2004/014382	02-19-2004	Rigel Pharmaceuticals, Inc.		<input type="checkbox"/> <input type="checkbox"/>
OTHER DOCUMENTS – NON-PATENT LITERATURE DOCUMENTS							
*Examiner Initials	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published					TRANSLATION YES NO
		Cores: An Automated Method for Generating Three-Dimensional Models of Protein/Ligand Complexes, Hare, Brian J., Journal of Chemistry (2004)47(19), 4731-4740					<input type="checkbox"/>
		Roles of Conformational and Positional Adaptability in Structure-Based Design of TMC 125-R165335 (Etravirine) and related non-nucleoside reverse transcriptase inhibitors that are highly potent and effective against wild-type and drug-resistant HIV-1 variants. Das, Kalyan; Journal of Medicinal Chemistry (2004), 47(10), 2550-2560					<input type="checkbox"/>
		Identification of Compounds with Nanomolr binding Affinity for Checkpoint Kinase-1 Using Knowledge-Based Virtual Screening. Lyne, Pauld D.; Journal of Medicinal Chemistry (2004) 47(8), 1962-1968					<input type="checkbox"/>
		Cyclin-dependent kinase 4 inhibitors as a treatment for cancer. Part 2: identification and optimization of substituted 2,4-bis anilino pyrimidines. Bioorganic & Medicinal Chemistry Letters (2203), 13(18), 2961-2966					<input type="checkbox"/>
EXAMINER SIGNATURE				DATE CONSIDERED			
*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.							